DNMT Inhibitors Increase Methylation in the Cancer Genome
DNA methyltransferase inhibitors (DNMTi) decitabine and azacytidine are approved therapies for myelodysplastic syndrome and acute myeloid leukemia, and their combinations with other anticancer agents are being tested as therapeutic options for multiple solid cancers such as colon, ovarian, and lung...
Saved in:
Main Authors: | Anil K. Giri (Author), Tero Aittokallio (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Target-specific compound selectivity for multi-target drug discovery and repurposing
by: Tianduanyi Wang, et al.
Published: (2022) -
What is synergy? The Saariselkä agreement revisited
by: Jing eTang, et al.
Published: (2015) -
From drug response profiling to target addiction scoring in cancer cell models
by: Bhagwan Yadav, et al.
Published: (2015) -
Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy
by: Ting Chen, et al.
Published: (2024) -
Judeans in Babylonia A Study of Deportees in the Sixth and Fifth Centuries BCE
by: Alstola, Tero
Published: (2019)